Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-02-13

Intellia Therapeutics, Inc.

Clinical-stage biotechnology company developing in vivo gene-editing therapeutics for genetic diseases.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Two clinical gates define a re-rating path

A clean lonvo-z registrational readout and credible commercialization plan can turn one-time editing into a scalable rare-disease franchise. ATTR-CM is the non-linear upside lever, but remains regulator-gated.

Analysis

Thesis

If lonvo-z posts clean registrational data and commercializes with a workflow moat (payer contracts, certified sites, registry), Intellia can become a scaled rare-disease franchise by 2031; any credible restart of ATTR-CM adds non-linear upside, while today’s valuation still reflects a heavy safety/regulatory discount.

Last Economy Alignment

AI makes discovery cheaper, but scarce value in therapeutics shifts to regulatory-grade clinical outcomes, safety playbooks, and proprietary longitudinal datasets—areas Intellia can compound if it clears its safety gates.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

10.2x (from 5 most recent analyses)

Reasoning

The setup is a de-risking ladder: (1) lonvo-z registrational data, (2) filing/acceptance, (3) launch execution in a payer- and site-workflow-heavy market. If Intellia turns “one-time therapy” into a repeatable access engine (outcomes-linked contracting, faster approvals, certified sites, patient registry), revenue can scale quickly and the multiple can re-rate as uncertainty collapses. ATTR-CM is upside, not required.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The dominant risk is regulatory permissioning after liver-safety events—continued holds or restrictive requirements can delay timelines and compress adoption. Second is commercialization friction for one-time therapies (coverage mechanics, outcomes tracking, site workflow). Third is financing/dilution if setbacks extend burn before meaningful product revenue.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new primary-source (SEC) updates in the last 7–10 days within the provided materials; near-term focus remains the next earnings update and the lonvo-z data window.
Risk narrative remains dominated by whether ATTR-CM gets an FDA-aligned path forward (and ultimately a hold lift).

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.19

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$23.94

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research